Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Last updated: January 14, 2026
Sponsor: Masonic Cancer Center, University of Minnesota
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Hiv Infections

Sarcoidosis

Primary Immunodeficiency Disorders

Treatment

Stem Cell Transplantation

Cyclophosphamide

Fludarabine phosphate 30 mg

Clinical Study ID

NCT01652092
2012OC055
MT2012-10C
  • Ages < 50
  • All Genders

Study Summary

This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of immunodeficiency or histiocytic disorder including the following:

  • Severe combined immunodeficiency (SCID - all variants)

  • Second bone marrow transplant (BMT) for SCID (after graft rejection)

  • Omenn's Syndrome

  • Reticular dysgenesis

  • Wiskott-Aldrich syndrome

  • Major histocompatibility complex (MHC) Class II deficiency (bare lymphocyte syndrome)

  • Hyper IgM Syndrome (CD40 Ligand Deficiency)

  • Common variable immunodeficiency (CVID) with severe phenotype

  • Chronic Granulomatous Disease (CGD)

  • Other severe Combined Immune Deficiencies (CID)

  • Hemophagocytic Lymphohistiocytosis (HLH)

  • X-linked Lymphoproliferative Disease (XLP)

  • Chediak-Higashi Syndrome (CHS)

  • Griscelli Syndrome

  • Langerhans Cell Histiocytosis (LCH)

  • Acceptable stem cell sources include:

  • HLA identical or 1 antigen matched sibling donor eligible to donate bone marrow

  • HLA identical or up to a 1 antigen mismatched unrelated BM donor

  • Sibling donor cord blood with acceptable HLA match and cell dose as per current institutional standards

  • Single unrelated umbilical cord blood unit with 0-2 antigen mismatch and minimum cell dose of >5 x 10^7 nucleated cells/kg as per current institutional guidelines

  • Double unrelated umbilical cord blood units that are:

  • up to 2 antigen mismatched to the patient

  • up to 2 antigen mismatched to each other

  • minimum cell dose of at least one single unit must be ≥ 3.5 x 10^7 nucleated cells/kg

  • combined dose of both units must provide a total cell dose of ≥ 5 x 10^7 nucleated cells/kg

  • Age: 0 to 50 years

  • Adequate organ function and performance status.

Exclusion Criteria

  • pregnant or breastfeeding

  • active, uncontrolled infection and/or HIV positive

  • acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy

Study Design

Total Participants: 57
Treatment Group(s): 9
Primary Treatment: Stem Cell Transplantation
Phase:
Study Start date:
September 04, 2012
Estimated Completion Date:
December 31, 2026

Study Description

Based on diagnosis and clinical history, a determination of the most appropriate regimen will be made based on the following prep plans:

Arm A: Fully Myeloablative Preparative Regimen, Arm B: Reduced Toxicity Ablative Preparative Regimen, Arm C: Reduced Intensity Conditioning, Arm D: No Preparative Regimen

Connect with a study center

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota 55455
    United States

    Site Not Available

  • Masonic Cancer Center, University of Minnesota

    Minneapolis 5037649, Minnesota 5037779 55455
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.